Urolog. pro Praxi, 2002; 1: 9-17

Karcinom prostaty - aktuální pohled

doc. MUDr. Dalibor Pacík CSc
Přednosta urologické kliniky FN Brno LF Masarykovy Univerzity Brno

Keywords: prostatic carcinom, diagnosis, epidemiology, treatment.

Published: December 31, 2002  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pacík D. Karcinom prostaty - aktuální pohled. Urol. praxi. 2002;3(1):9-17.

Medicína, a tedy i urologie, prodělávají v posledním desetiletí dramatické změny. Jsme svědky nevídaného pokroku, který přináší velmi často i zásadní změny do zavedených postupů a přitom je ku prospěchu našim pacientům. Co platilo včera, často neplatí dnes a už vůbec nebude pravda zítra. Tyto změny je velmi obtížné sledovat, zejména při každodenním zavalení klinickou rutinní praxí. A přitom je to naše povinnost. Cílem tohoto článku je přiblížit aktuální informace z oblasti jedné z nejzávažnějších uroonkologických diagnóz - karcinomu prostaty.

Prostatic Carcinoma - a Current Viewpoint

Medicine and thus urology have been facing dramatic changes in recent years. We have been witnessing unprecedented advances that very often have brought fundamental modifications of the existing management strategy and which our patients can profit from. What was true yesterday may not be true today and certainly will definitely not be true tomorrow. These changes cannot be easily pursued during the enormous amount of daily work required. However, this is our obligation. The aim of this article is to highlight the up to date information of one of the most serious uro-oncological diagnosis - prostatic carcinoma.

Download citation

References

  1. Abbou, et al. Urology 2000; 55: 630-634.
  2. Amling, et al. Long-Term Hazard of Progression After Radical Prostatectomy for Clinically localized Prostate Cancer: Continued Risk of Biochemical failure after 5 years. J Urol 2000; 164: 101-105. Go to original source... Go to PubMed...
  3. Anscher, et al. Int J Rad Oncol Biol Phys 2000; 48: 369-375. Go to original source... Go to PubMed...
  4. Aus G, et al. EAU Guidelines on prostate cancer. Eur urol 2001; 40: 97-101. Go to original source... Go to PubMed...
  5. Babaian RJ, et al. Urology 2000; 56: 1000-1006.
  6. Becker C, et al. Urology 2000; 55: 694-699.
  7. Blasko JC, et al. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma (DCRT) for High Grade Postate Cancer: a Multi-institutional Review. Radiotherapy and Oncol 2000; 57: 273-278. Go to original source... Go to PubMed...
  8. Borboroglu PG, et al. Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. J Urol 2000; 163: 158-162. Go to original source... Go to PubMed...
  9. Carter HB. Urology 2000; 55: 796-799.
  10. Catalona WJ, et al. Urology 2000; 56: 255-260.
  11. Catalona W. Urology 2000; 55: 791-795.
  12. Culine S, Droz JP. Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: A decade of progress? : Chemotherapy in advanced androgenindependent prostate cancer 1990-1999: a decade of progress. Ann Oncol 2000; 11: 15231. Go to original source... Go to PubMed...
  13. De la Taille E, et al. J Urol 2000; 164: 1229-1234.
  14. Epstein JI, et al. Urology 2000; 56: 283-288.
  15. Farrugia, et al. Stibestrol plus adrenal suppression as salvage trentament patients failing treatment with luteinizing hormone - releasing hormone analogues and orchitectomy. BJU Int 2000; 85: 1069-1073. Go to original source... Go to PubMed...
  16. Fiveash, et al. 3D Conformal Radiation Therapy. Int J Rad Oncol Biol Phys 2000; 47: 335-342. Go to original source... Go to PubMed...
  17. Gelblum DY, Potters L Int J Rad Oncol Biol Phys 2000; 48: 119-124. Go to original source... Go to PubMed...
  18. Greenlee RT, et al. Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 15-36. Go to original source... Go to PubMed...
  19. Grossfeld, et al. Managenent of a positive Surgical Margin after Radical Prostatectomy: Decision Analysis. J Urol 2000; 164: 93-99. Go to original source... Go to PubMed...
  20. Guillonneau and Vallancien. Laparoscopic radical prostatectomy: The Montsouris technique. J Urol 2000; 163: 1643-1649. Go to original source... Go to PubMed...
  21. Helzisouer KJ, et al. Association Between alpha-Tocopherol, Selenium, and Subsequent Prostate Cancer. JNCI 2000; 92: 2018-2023. Go to original source... Go to PubMed...
  22. Horowitz EM, and Hanks GE. External beam radiation therapy for prostate cancer. Cancer J Clin, 50, 2000, s. 349-375. Go to original source... Go to PubMed...
  23. Hsing AW, et al. Body Size and Prostate Cancer: A Population-based Case-Control Study in China. Cancer Epid, Biomark and Prevention 2000; 9: 1335-1341.
  24. Jacob, et al. Laparoscopic radial prostatectomy: preliminary results. Eur Urol 2000; 37: 615. Go to original source... Go to PubMed...
  25. Kaaks R, et al. Plasma androgens, IGF-1, body size, and prostate cancer risk: a synthetic review. Prostate Cancer and Prostatic Diseases 2000; 3: 157-172. Go to original source... Go to PubMed...
  26. Kattan MW, et al. The Definition of Biochemical Failure in Patients treated with Definitive Radiotherapy. Int J Rad Oncol Biol Phys 2000; 48: 1469-1474. Go to original source... Go to PubMed...
  27. Kelada, et al. The glutathione S-Transferase and Genothypes in the Etiology of Prostate Cancer: Genotype-Enviironment Interactions with Smoking. Cancer Epidemiol, Biomarkers and Prevention 2000; 9: 1329-1334.
  28. Kelly WK, et al. Paclitaxel, Estramustine Phosphate and carboplatin in Patients with Advanced Prostate Cancer. J Clin Oncol 2001; 19: 44-53. Go to original source... Go to PubMed...
  29. Koppie, et al. Transrectal ultrasound quided prostate biopsy - defining new standard. J Urol 2000; 164: 81-88. Go to original source... Go to PubMed...
  30. Matoušková M, et al. Doporučený postup ČLS JEP - Karcinom prostaty, 2001.
  31. Mayer F, et al. Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure. Urol 1999; 162: 2024-2028. Go to original source... Go to PubMed...
  32. Modern Prostate Brachytherapy Radge et al.: Modern prostate brachytherapy. Cancer J Clin 2000; 50: 380-393. Go to original source... Go to PubMed...
  33. Laufer M, et al. Complete Androgen Blockade for Prostate Cancer: What went wrong? J Urol 2000; 164: 3-9. Go to original source... Go to PubMed...
  34. Leibovich BC, et al. Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin. J Urol 2000; 163: 1178-1182. Go to original source... Go to PubMed...
  35. Lotufo PA, et al. Cigarette smoking and risk of prostate cancer in the physicians: Health study (US). Int J Cancer 2000; 87: 141-144. Go to original source... Go to PubMed...
  36. Newling D. Eur Urol 2001; 39: 15-21.
  37. Nutting, et al. Intensity modulated radiation therapy: a clinical review. Brit J Radiol 2000; 73: 459-469. Go to original source... Go to PubMed...
  38. Olumi AF, et al. Urology 2000; 56: 273-277.
  39. Oh WK, et al. Urology 2001; 57: 122-126.
  40. Papapoulos S E, et al. Bisphosphonates in the Management of Prostate Carcinoma Metastatic to the Skeleton. Cancer 2000; 88: 3047-3053. Go to original source...
  41. Perez CA. Three-Dimensional Conformal Therapy or Standard Irradiation in Localized Carcinoma of Prostate: Preliminary Results of a Nonrandomized Comparison. Int J Rad Oncol Biol Phys 2000; 47: 629-637. Go to original source... Go to PubMed...
  42. Petrylak DP. Sem Oncol 2000; 27: 24-29.
  43. Pinover WH, et al. Defining the Appropriate Radiation Dose for Pretreatment PSA 10 ng/mL Prostate cancer. In J Rad Oncol Biol Phys 2000; 47: 649-650. Go to original source... Go to PubMed...
  44. Platz, et al. Racial variation in Prostate Cancer Incidence and in Hormonal Systém Markers Among Male Health Professionals. JNCI 2000; 92: 2009-2017. Go to original source... Go to PubMed...
  45. Pollack, et al. Int J Rad Oncol, Biol, Phys 2000; 48: 507-512. Go to original source...
  46. Presti JC, et al. Optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: Results of prospective clinical trial. J Urol 2000; 163: 179-180. Go to original source... Go to PubMed...
  47. Radge, et al. Cancer 2000; 89: 135-141.
  48. Santis WF, et al. Early catheter removal in 100 consecutive patients undergoing radical retropubic prostatectomy. BJU Int 2000; 85: 1067-1068. Go to original source... Go to PubMed...
  49. Shaneyfelt T, et al. Hormonal Predictors of Prostate Cancer: A Meta-Analysis. J Clin Oncol 2000; 18: 847-853. Go to original source... Go to PubMed...
  50. Schiarra A, et al. Intermittent androgen deprivation (IAD) in patients with biochemical failure after radical retropubic prostatectomy (RRP) for clinicaly localized prostate cancer. World J Urol 2000; 18: 392-400. Go to original source... Go to PubMed...
  51. Smith RA, et al. American Cancer Society Guidelines for the Early Detection of Cancer: Update of Early Detection Guidelines for Prostate, Colorectal, and Endometrial Cancers. CA Cancer J Clin 2001; 51: 38-75. Go to original source... Go to PubMed...
  52. Stattin P, et al. Plasma Insulin-Like Growth Factor-I, Insulin-Like Growth Factor-Binding Proteins, and Prostate Cancer Risk: a Prospective Study. JNCI 2000; 92: 1910-1917. Go to original source... Go to PubMed...
  53. Valincenti R, et al. Survival Advantage From Higher-Dose Radiation Therapy for Clinical Localized Prostate Cancer Treated on the Radiation Therapy Oncology Group Trials. J Clin Oncol 2000; 18: 2740-2746. Go to original source... Go to PubMed...
  54. Valicenti RK and Gomella LG. Durable Efficacy of Adjuvant Radiation Therapy for Prostate Cancer: Will the benefit Last? Sem Urol Oncol 2000; 18: 115-120.
  55. Walsh PC. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with mode-positive prostate cancer. J Urol 2000; 164: 246-247.
  56. Walsh PC. Radical prostatectomy for localized prostate cancer provides cancer control with excellent quality of life: a structured debate. J Urol 2000; 163: 1802-1807. Go to original source... Go to PubMed...
  57. Wirth M, et al. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progresion. Urology 2001; 58: 146-151. Go to original source... Go to PubMed...
  58. Wirth M, et al. Delaying/Reducing the Risk of Clinical Tumor Progression after Primary Curative procedures. European urology 2001; 40 (suppl 2): 17-23. Go to original source... Go to PubMed...
  59. Young CD, et al. The Impact of Race on Freedom From Prostate-Specific Antigen Failure in Prostate Cancer Patients Treated With Definitive Radiation Therapy. Sem Urol Oncol 2000; 18: 121-126.
  60. Zelefsky MJ, et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiotherapy and Oncology 2000; 55: 241-249. Go to original source... Go to PubMed...
  61. Zelefsky MJ, et al. Five Zear Biochemical Outcome and Toxicity with Transperineal CT-Planned Permanent I-125 Prostate Implantation for patients with Localized Prostate Cancer. Int J Rad Oncol Biol Phys 2000; 47: 1261-1266. Go to original source... Go to PubMed...
  62. Zelefsky MJ, et al. J Clin Oncol 2000; 18: 1936-1941.
  63. Zhang WM, et al. Urology 2000; 56: 267-272.
  64. Zhao XY, et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nature Medicine 2000; 6: 703-706. Go to original source... Go to PubMed...




Urology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.